Efficacy and safety of GZR18 injected every 2 weeks (Q2W) in participants without type 2 diabetes, who have obesity or are overweight: a randomized, tirzepatide- and placebo-controlled study
This study will look at how an investigational drug called GZR18 works in your body by:
Prolongation of GLP-1 Adherence when using Continuous Glucose Monitoring
The primary purpose of this study is to utilize the FSL3 to help prolong the length of time people with diabetes maintain adherence to GLP-1 and GIP/GLP-1 antagonists. Subjects with type 2 diabetes who are newly beginning glucagon-like peptide 1 (GLP-1) and dual gastric inhibitory polypeptide/glucagon-like peptide 1 (GIP/GLP-1) agonist therapy will be assigned to […]
A Phase II Randomised, Doubleblind, Placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD6234 in participants living with overweight or obesity with Type 2 Diabetes who are on a stable dose of GLP-1 Receptor Agonist
We are doing this study to learn more about how safe the study drug AZD6234 is and how it affects your medical condition of overweight or obesity with type 2 diabetes when you are given the study drug AZD6234 along with a specific therapy called glucagon like peptide-1 receptor agonist (GLP-1 RA). Additional aims of […]
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism
The purpose of this study is to evaluate if Armour Thyroid is safe and effective in the treatment of hypothyroidism. This study will compare the effect of Armour Thyroid on hypothyroidism and its safety with synthetic drug T4 (Levothyroxine). The number of FDA-approved and commercially available options for the treatment of hypothyroidism are limited. Currently, […]
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multiple-dose, Crossover Study of the Effect of ZT-01 on Frequency of Nocturnal Hypoglycemia in Type 1 Diabetes Mellitus
The study drug ZT-01 is designed to inhibit somatostatin, a hormone that inhibits the glucagon response to hypoglycemia. Thus, ZT-01 may be able to restore glucagon production to prevent hypoglycemia, which could improve both health and quality of life in people with T1DM. The purpose of this study is:
